The company made this announcement during trading hours today, 27 December 2007

Meanwhile, BSE Sensex was up 50.84 points or 0.25% to 20,243.36.

On BSE 38.61 lakh shares were traded in the counter. The stock had an average daily volume of 5.78 lakh shares in the past one quarter.

The stock hit a high of Rs 54.80 and a low of Rs 46 so far during the day. The stock hit a 52-week high of Rs 54.80 on 19 December 2007 and a 52-week low of Rs 27.98 on 28 December 2006.

The small-cap scrip had outperformed the market over the past one month till 26 December 2007, gaining 38.69% as compared to the Sensexs return of 5.57%. It had also outperformed the market in the past one quarter, rising 27.67% as compared to the Sensexs rise of 17.74%.

The companys current equity is Rs 11.56. Face value per share is Rs 5.

The current price of Rs 53.35 discounts Q2 September 2007 annualized EPS of Rs 0.40 PE multiple of 133.38.

This is Suven's first product patent in US. The granted claims of the patent include the class of selective Serotonin receptor affinity compounds discovered by Suven and are being developed as therapeutic agents. The compounds are useful in the treatment of neurodegenerative disorders like Alzheimer's Parkinson, Schizophrenia and Huntington's.

On 28 November 2007, the company received patent for its product from European patent office for the treatment of neurodegenerative diseases.

On 31 October 2007, Suven Life Sciences announced that two of its new chemical entities for the treatment of disorders associated with neurodegenerative diseases were granted patents in Australia and New Zealand and these patents are valid until 2022.

On 23 October 2007, Suven Life Sciences announced that the Indian Patent Office had granted three product patents to three new chemical entities (NCEs) of the company for the treatment of disorders associated with neurodegenerative diseases and theses patents are valid until 2022.

Suven Life Sciences net profit declined 53.4% to Rs 1.16 crore on 0.1% fall in net sales to Rs 27.84 crore in Q2 September 2007 over Q2 September 2006.

Suven Life Sciences principal activity is to design, manufacture and the supply of bulk active, drug intermediates and fine chemicals to the life science industry. The company mainly operates in the USA, Europe, Asia and India.

Powered byCapital Market - Live News